JCJonathan D. Cicci

Jonathan D. Cicci

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jonathan D. Cicci has a total of 44 co-authors. Here are the top co-authors by number of shared publications:

  • Brent N. Reed

    Organizational Science Program and Department of Psychological Science, University of North Carolina at Charlotte, Charlotte, USA

    4 shared publications
  • Craig R. Lee

    Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy University of North Carolina at Chapel Hill Chapel Hill North Carolina USA

    2 shared publications
  • Akinyemi Oni‐Orisan

    Eshelman School of Pharmacy University of North Carolina Chapel Hill North Carolina

    1 shared publication
  • Alexis K. Williams

    Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, Chapel Hill, NC, USA

    1 shared publication
  • Bethany A. Kalich

    Assistant professor, Department of Pharmacy Practice, Feik School of Pharmacy, University of the Incarnate Word, San Antonio, Texas

    1 shared publication
  • Brittany J. Tefft

    Department of Pharmacy, Mayo Clinic, Rochester, Minnesota

    1 shared publication

Latest Publications

  • Frequency and clinical outcomes of CYP2C19 genotype-guided escalation and de-escalation of antiplatelet therapy in a real-world clinical setting

    by Jesse Martin, Alexis K. Williams, Melissa D. Klein, Vindhya B. Sriramoju, Shivanshu Madan, Joseph S. Rossi, Megan Clarke, Jonathan D. Cicci, Larisa H. Cavallari, Karen E. Weck, et al.


  • Open Access

    Loperamide overdose causing torsades de pointes and requiring Impella temporary mechanical support: a case report

    by Jonathan D Cicci, Sarah M Jagielski, Megan M Clarke, Robert A Rayson, Matthew A Cavender

    Background: Loperamide is a widely available oral μ-opioid receptor agonist, and loperamide abuse is increasing by those seeking intoxication. Loperamide has potent QTc-prolonging properties, placing patients at risk for ventricular arrhythmias and sudden cardiac death.Case summary: A 23-year-old woman was found to be in pulseless ventricular fibrillation with a QTc of 554 ms and received multiple defibrillations and IV lidocaine. Her toxicology studies were negative. She subsequently experienced multiple episodes of torsades de pointes and was found to be in cardiogenic shock with a left ventricular ejection fraction of 5%. Following multiple defibrillations, an Impella® mechanical circulatory support device was placed, and she was given IV magnesium and IV lidocaine. After mechanical circulatory support was withdrawn, she experienced major bleeding and was found to have a deep vein thrombosis, bilateral radial artery thrombosis, and multiple pulmonary embolisms in the setting of heparin-induced thrombocytopenia. After stabilizing, she admitted to taking 80 tablets of loperamide 2 mg in pursuit of euphoria.Discussion: Loperamide is an increasingly popular agent of abuse. Loperamide-associated ventricular arrhythmias are rare with normal doses but more common with high doses, chronic ingestion, or interacting medications. Loperamide cardiotoxicity may be prolonged due to a long half-life and accumulation. Loperamide abuse may be under-recognized, leading to delays in treatment. Intravenous fluids, magnesium supplementation, chronotropes, transcutaneous or transvenous pacing, and defibrillation may be helpful in mitigating loperamide-associated polymorphic ventricular tachycardia. Clinicians should monitor for drug interactions in patients taking loperamide and screen for electrocardiographic abnormalities in those taking chronic or high-dose loperamide.


  • Continuous Care Provided Through Comprehensive Medication Management in an Acute Care Practice Model

    by T. David Marr, Nicole R. Pinelli, Jamie A. Jarmul, Kayla M. Waldron, Stephen F. Eckel, Jonathan D. Cicci, Jill S. Bates, Lindsey B. Amerine

    Background: Pharmacy practice models that foster pharmacists’ accountability for medication-related outcomes are imperative for the profession. Comprehensive medication management (CMM) is an opportunity to advance patient care. Objective: The objective of this study was to evaluate the impact of a CMM practice model in the acute care setting on organizational, patient, and financial outcomes. Methods: Three adult service lines focused on at-risk patients identified using internal risk stratification methodology were implemented. Core CMM elements included medication reconciliation, differentiated clinical pharmacy services, inpatient MTM consultations, discharge services, and documentation. Mixed methods compared the effect of the CMM model before and after implementation. Historical patients served as comparative controls in an observational design. Pharmacists completed a 60-minute interview regarding their experiences. Qualitative data were analyzed using thematic coding to characterize perception of the model. Results: Three pharmacists implemented the model on cardiology, hematology/oncology, and surgery transplant services and provided services to 75 patients during the study. A total of 145 medication-related problems were identified and resolved. CMM was associated with a nonsignificant reduction of 8.8% in 30-day hospital readmission rates (P = 0.64) and a 24.9% reduction in 30-day hospital utilization (P = 0.41) as well as a significant reduction of 86.5% in emergency department visits (P = 0.02). Patients receiving discharge prescriptions from our outpatient pharmacies increased by 21.4%, resulting in an 11.3% increase in discharge prescription capture and additional revenue of $5780. Themes identified from qualitative interviews included CMM structure, challenges, value, and resources. Conclusion: This study demonstrated successful implementation of a CMM model that positively affected organizational, patient, and financial outcomes.


  • Open Access

    From Pilot to Practice: A Trainee-Integrated Pharmacy Practice Model in Cardiology

    by Bethany A. Kalich, Jonathan D. Cicci, Shailly Shah, Brent N. Reed

    OBJECTIVES Problems related to medication use portend poor outcomes, but resources for expanding clinical pharmacy services are limited. We conducted a pilot study in the area of cardiology to determine the impact and feasibility of a trainee-integrated pharmacy practice (TIPP) model comprised of pharmacy residents and a clinical pharmacist.


  • Safety of Nonsteroidal Antiinflammatory Drugs in Patients with Cardiovascular Disease

    by Ilya M. Danelich, Sampaguita S. Wright, Jennifer M. Lose, Brittany J. Tefft, Jonathan D. Cicci, Brent N. Reed

    Nonsteroidal antiinflammatory drugs (NSAIDs) are used in the management of a variety of conditions, but their prevalence is likely underreported as a result of widespread availability and the perception that nonprescription therapies are unnecessary to report during medication history taking. However, NSAIDs are associated with a number of adverse effects, especially in patients with cardiovascular disease (CVD). Patients with CVD and comorbidities for which NSAIDs may provide symptomatic relief (e.g., osteoarthritis, rheumatoid arthritis) tend to be older, which places them at greater risk of harm. For these reasons, the use of NSAIDs in patients with CVD is a significant public health concern. An understanding of the risks associated with NSAIDs is critical for clinicians across practice settings. In this review, we detail the safety of NSAIDs in patients with CVD, provide recommendations on their use in specific disease states, and discuss therapeutic alternatives.


  • Implementation and Evaluation of a CYP2C19 Genotype-Guided Antiplatelet Therapy Algorithm in High-Risk Coronary Artery Disease Patients

    by John Andrew Lee, Craig R Lee, Brent N Reed, David C Plitt, Melissa J Polasek, Lucius A Howell, Jonathan D Cicci, Kristen E Tasca, Karen E Weck, Joseph S Rossi, et al.

    An algorithm that uses clinical factors and CYP2C19 genotype to guide P2Y12 inhibitor selection in high-risk patients undergoing percutaneous coronary intervention was implemented at our institution. We sought to evaluate use of this algorithm and identify which factors influenced P2Y12 inhibitor selection. This retrospective cohort study included 264 patients receiving percutaneous coronary intervention from July-December 2012. CYP2C19 genotype was obtained in 229 patients; of these, 30% were intermediate or poor metabolizers. CYP2C19 intermediate or poor metabolizer phenotype was among the strongest predictors for selecting prasugrel or ticagrelor as maintenance therapy (p < 0.001), and was the only significant predictor of a change in therapy (p < 0.001). These findings suggest that using CYP2C19 genotype to guide P2Y12 inhibitor selection is feasible. Original submitted 27 October 2014; revision submitted 19 December 2014.


  • Acute Decompensated Heart Failure: Evolving Literature and Implications for Future Practice

    by Jonathan D. Cicci, Brent N. Reed, Elizabeth B. McNeely, Akinyemi Oni‐Orisan, J. Herbert Patterson, Jo E. Rodgers

    Acute decompensated heart failure (ADHF) is associated with substantial morbidity and mortality, and represents a considerable financial burden to society. Historically, few prospective, randomized, double‐blinded trials have investigated the optimal management of ADHF, and most guideline recommendations are based primarily on expert opinion. However, in the last decade, a considerable amount of research has added to the understanding of the management of ADHF in both patients with fluid overload and low cardiac output. In addition, as mechanical circulatory support devices and heart transplantation continue to evolve, significant advances have also been made with regard to the proper selection of patients for advanced surgical options. Finally, several novel pharmacologic agents have shown promise in early trials and may represent the next steps in ADHF management. Although advances have been made over the past decade, many questions remain.